Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rad52 inactivation is synthetically lethal with BRCA2 deficiency

8 Dec 2010

Abstract excerpt

Synthetic lethality is a powerful approach to study selective cell killing based on genotype. We show that loss of Rad52 function is synthetically lethal with breast cancer 2, early onset (BRCA2) deficiency, whereas there was no impact on cell growth and viability in BRCA2-complemented cells. The frequency of both spontaneous and double-strand break-induced homologous recombination and ionizing radiation-induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21148102
DOI: 10.1073/pnas.1010959107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rad52 inactivation is synthetically lethal with BRCA2 deficiencyPMID 21148102Read ↗

Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic AdvancementSemantic proximity Read ↗

Reappearance from Obscurity: Mammalian Rad52 in Homologous RecombinationSemantic proximity Read ↗

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer TherapiesSemantic proximity Read ↗

RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombinationSemantic proximity Read ↗

Emerging Roles of RAD52 in Genome MaintenanceSemantic proximity Read ↗

Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.Semantic proximity Read ↗

Genome-wide analysis of Rad52 foci reveals diverse mechanisms impacting recombination.Semantic proximity Read ↗

Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.Semantic proximity Read ↗

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.Semantic proximity Read ↗

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsSemantic proximity Read ↗

The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.Semantic proximity Read ↗

The enigmatic oncogene and tumor suppressor‐like properties of RAD54B: Insights into genome instability and cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.